Get started

Covid-2019

$SPCB Wins COVID-19 Quarantine Project $3 Million per MonthSuperCom Wins COVID-19 Quarantine Compliance Project with the Israeli Government Valued at an Estimated $3 Million per Month in Recurring Revenues Initial project term of 3 months, with potential extension for up to 36 months This nationwide project is expected to commence next week, along with contract signing, for an initial term of 3 months, with an option to be extended for up to 36 months. The project is billed at a per-unit per-day rate is expected to generate approximately $3 million per month in recurring revenues for SuperCom. However, revenue may increase or decrease based on actual usage. finance.yahoo.com
NASDAQ:SPCB
by AlenCiken
Brent crude soars on OPEC surpriseThursday's OPEC+ meeting became a market-mover event, as members announced that production cuts would be extended in April. This caught the market completely off guard, as OPEC+ was widely expected to raise output by 500,000 barrels per month. Instead, OPEC+ has opted to hold back some 9.2 million barrels from the market each day, until at least the beginning of May. Crude responded to the OPEC+ announcement with sharp gains. Brent crude jumped 4.84% on Thursday, its highest one-day gain in two weeks. With an additional gain of close to 1 percent on Friday, Brent crude punched above the USD 68 line for the first time since January 2020. Oil prices have soared since November 2020, with Brent crude jumping a staggering 76% during that time. The key question now for investors and traders is whether the uptrend will continue, or will we see a levelling off in oil prices. The fact that the global economy is slowly recovering from Covid-19 should translate into higher demand for crude and maintain upward pressure on oil prices. At the same time, OPEC members are notorious for not abiding by production limits, which could put a curb on higher prices. In other news on the crude oil front, the EIA Crude Oil inventories report showed a record-high surplus of 21.6 million barrels. However, this figure was distorted by the recent Texas storm, which resulted in huge stockpiles due to refiners being unable to take on crude shipments. Prior to today's EIA release, nine of the past 11 readings have shown drawdowns, and with significant pent-up demand in the US economy, this trend could well continue. Brent crude has broken above resistance at the overnight high of 67.72 and double top, with the next resistance at 71.52, which has held since May 2019. Support is distant between USD62.03 and USD62.48.
FX_IDC:USDBRO
by OANDA
Strong pan-coronavirus effectiveness of clinical drug candidatesPan-coronavirus Clinical Drug Candidates for the Treatment of COVID-19 Are Highly Effective in Pre-clinical Cell Culture Studies Performed in Preparation of FDA Pre-IND Application $NNVC reported yesterday on the strong pan-coronavirus effectiveness of its two COVID-19 clinical drug candidates for which the Company is preparing a pre-IND application. NV-CoV-2 is the Company's broad-spectrum anti-coronavirus clinical lead drug candidate for the treatment of COVID-19 patients based on its nanoviricides® platform. $NNVC is also developing NV-CoV-2-R, a drug treatment that combines the power of both NV-CoV-2 and remdesivir in a single drug that encapsulates and protects remdesivir inside NV-CoV-2. Both NV-CoV-2 and NV-CoV-2-R are expected to work against most, if not all , coronaviruses and their variants, based on the Company's findings on their pre-clinical effectiveness discussed below. NV-CoV-2 and NV-CoV-2-R were found to be highly effective in comparison to remdesivir against two distinctly different coronaviruses in our new cell culture studies leading towards a pre-IND application and thereafter an IND submission for these COVID-19 drug candidates. The Company intends to report on the results of these studies in its pre-IND application to the US FDA to obtain guidance regarding human clinical trials for treatment of COVID-19 patients. Additionally, the Company is actively seeking opportunities to engage appropriate sites for human clinical trials. Further, the Company is engaged in the preparation of clinical trial protocols and other activities that would be necessary for submitting an IND application to the US FDA. The Company has developed NV-CoV-2 based on its platform nanoviricides® technology. This approach enables rapid development of new drugs against a number of different viruses. finance.yahoo.com
AMEX:NNVC
by AlenCiken
2
Reduced recovery time in mild-to-moderate COVID-19 patientsNew Phase 3 Clinical Study Finds Nutritional Protocol Including Nicotinamide Riboside Accelerates Recovery in Mild-to-Moderate COVID-19 Patients New Phase 3 study results show added nutritional protocol reduces recovery time in mild-to-moderate COVID-19 patients The addition of the nutritional protocol, or combined metabolic activators (CMA), to the Turkish standard of care not only reduced recovery time but improved liver health and decreased levels of inflammatory markers. finance.yahoo.com
NASDAQ:CDXC
by AlenCiken
Covid-19 vacine should be of benefit, Gold 4hr and daily Nice>>>Gold showing signs of a more dominant progress north, to really understand where I am going with this, you need to view my previous charts linked below. I at first seen a possible break north in the early new year, this started as planned, alas the new variant came and further decline progressed, I outlined this possible drop in my previous charts, but did not have my fingers crossed long enough. That said the yellow metal did show signs of weakening further, but much over the last few weeks has seen confidence become more apparent, this in part is due to an effective vaccine, less restrictions globally as lock downs become less restrictive, however gold does have a tendency to follow its own path and other strategies have gone in producing this idea, fractal method, fib and others. Note I did change the idea between the 4hr and daily in its path north. Areas to look for 1828,1858,1900,1928,1958 and 2015 For further information on this idea please PM me
OANDA:XAUUSDLong
by JohnLiv
Why $IFMK Skyrocketed in February? indoor dining shutdownsWhy $IFMK Skyrocketed in February There does not appear to be any direct news from the company. But it seems like that there was some coordination by day traders on social media. $IFMK shares were buoyed — thanks to discussions and speculation on Twitter and Twitter hashtags at the start of the month. iFresh Inc is an Asian/Chinese grocery supermarket chain in the North-Eastern U.S. providing food and other merchandise hard to find in mainstream grocery stores. The company generates a majority of its revenue from its retail segment. The other positive factor for the $IFMK is the surging Food delivery in NYC as indoor dining shutdowns continue (based out of nyc), due to covid 19. www.benzinga.com twitter.com
I
by AlenCiken
OCGN - how to play the COVAXIN news !OCGN: What do they do: mainly focus on developing eye disease therapy. they stepped into the Covid vaccine play and they have a strong product coming – COVAXIN –get this : vaccine can be at room temperature that is huge! transporting and storing with cooling can triple the costs and Pfizer’s vaccine has to be in cooling conditions and if I am not mistaken – double-check me on it – except AstraZeneca all of them need cooling. The vaccine of Ocugen is in cooperation with Bharat Biotech. the vaccine is supposed to be stronger against different strains of covid that are emerging …. The reason for all the noise is in the fine print -they closed a damn good deal on the sales in the U.S – they will receive 45% of profits with no upfront payment (someone was drunk when he agreed to that deal LOL)… so price target given by Roth Capital is 8$ -don’t agree – I think in the next year if all goes well this stock is above 15$ if we factor in the “meme” market going on could be much more and much faster but let's stay conservative. Ok lets talk shop – technical: POC (point of control) is not good – 3,18 but I am certain it will rise in the upcoming week – remember POC is like a “magnet” it will attract the price to it for obvious reason. Volume: average volume is 63M, last 2 days trading above 100M. 50% line of retracement is 3.95 (round it up to the 4$ area – its always areas not specific numbers ) which means we will need to see the golden number getting touched sooner or later (again consider “meme” market conditions are extremely abnormal) 4.5$ -6$ needs to be retested – there needs to be a retracement to that area with some sideways trend before we can say let’s see 8$ - in normal market conditions…. Notice on the chart the yellow square showing ling upper wicks meaning buying power got very weak – matches the volume orders on the left (the colors are somewhat faded meaning it needs accumulation), reversal signal. The red box in the lower part of the chart is the forbidden zone – it is the other side of the POC and the stock flew through that price too quick so if we see a pullback to the POC line we may see a sell-off to that area- don’t believe this will happen so soon as sentiment is very high Bottom line – I think we need to see some pull back the upcoming days before the stock goes higher to the next level of 7$-usually happens after a 2-3 days rally and once that is done we can target 7$+. Please keep in mind we are trading on a very speculative market and everything is highly inflated along with 1.9T $ coming and meme trend this is a very risky market and using my analysis on it can mean shit because it is NOT BEHAVING like it should at all !! FDGT will wait for a pullback before entering as the trend doesn’t look healthy This is not a recommendation of any sort Trader safe and be safe – we are the traders union and we trade by our own rules!
NASDAQ:OCGNLong
by FDGT_academy
OCGN and Bharat Biote Announce Execution of Definitive AgreementOcugen and Bharat Biotech Announce Execution of Definitive Agreement for the Commercialization of COVAXIN™ in the US Market. Definitive Agreement provides details of the previously announced intent to co-develop COVAXIN™ for the US market. Ocugen and Bharat Biotech to share US commercialization profits. Ocugen to receive initial supply of COVAXIN™ doses from Bharat Biotech upon authorization from US regulatory authorities while it ramps up manufacturing in the US. COVAXIN™ received EUA (Emergency Use Authorization) in India in January and is currently in a fully enrolled Phase 3 clinical trial involving 25,800 patients. COVAXIN™ (whole-virion inactivated COVID-19 vaccine candidate) effectively neutralizes UK variant of SARS-Cov-2 reducing the possibility of mutant virus escape. today announced they have entered into a definitive agreement to co-develop, supply, and commercialize Bharat Biotech’s COVAXIN™ , an advanced stage whole-virion inactivated COVID-19 vaccine candidate, for the United States market. Ocugen will have US rights to the vaccine candidate and will be responsible for clinical development , regulatory approval (including EUA) and commercialization for the US market . B harat Biotech will supply initial dose s to be used in the US upon Ocugen’s receipt of an EUA. In addition, Bharat Biotech will support the technology transfer for manufacturing in the US . In consideration for the exclusive license to the US market, Ocugen will share the profits from the sale of COVAXIN™ in the US market with Bharat Biotech, with Ocugen retaining 45% of the profits. In preparation for the development of COVAXIN™ in the US, Ocugen’s Vaccine Scientific Advisory Board and Ocugen management have initiated discussions with the U.S. Food & Drug Administration (FDA) and the Biomedical Advanced Research and Development Authority (BARDA) to develop a regulatory path to EUA and, eventually, biologics license application (BLA) approval in the US market for COVAXIN™. Ocugen is also in active discussions with manufacturers in the US to produce a significant number of doses of COVAXIN™ to support its US immunization program. H.C. Wainwright analyst Swayampakula Ramakanth raised his rating on Ocugen's stock on Thursday from neutral to buy and placed a $4.50 price forecast on its shares. Ramakanth cheered Ocugen's recent deal with India-based vaccine developer Bharat Biotech to potentially bring Covaxin, a COVID-19 vaccine candidate, to the U.S. market. Ramakanth posits that Covaxin could induce broader immunity and better protection against new coronavirus strains than the COVID-19 vaccines that have received emergency use authorization in the U.S. He also highlighted Covaxin's potential logistical advantages, due to its less onerous temperature storage requirements. Roth Capital analyst Zegbeh Jallah, meanwhile, believes Ocugen's share price could rise to as high as $8. Jallah applauded the structure of the deal, which gave Ocugen a 45% share of the potential profits from Covaxin's U.S. sales without requiring it to make an upfront payment to Bharat Biotech . Jallah's price target represents potential gains for investors of roughly 52% from Ocugen's closing price on Friday. Much of Ocugen's future growth prospects now rest on its ability to obtain emergency use authorization for Covaxin in the U.S . Thus, investors should brace for volatility in Ocugen's stock price as it advances toward clinical trials.
NASDAQ:OCGN
by AlenCiken
4
Lexaria Provides Guidance on Upcoming R&DLexaria Bioscience Corp. Announces Uplisting to Nasdaq Capital Market and Pricing of $9.6 Million Upsized Public Offering Lexaria also announced the pricing of an underwritten public offering (the "Offering") of 1,828,571 units, each unit consisting of one share of common stock and one warrant to purchase one share of common stock at a public offering price of $5.25 per unit (all prices in US$). The shares of common stock and warrants comprising the units are immediately separable and will be issued separately, but will be purchased together. The warrants have an exercise price of $6.58 per share, are immediately exercisable and will expire five years following the date of issuance. The Company has granted the underwriter a 30-day option to purchase up to an additional 274,285 shares of common stock and/or warrants to purchase up to 274,285 shares of common stock. finance.yahoo.com Lexaria Provides Guidance on Upcoming R&D Lexaria recently closed an oversubscribed financing of US$11 million that has greatly enhanced the Company's ability to conduct applied R&D designed to evidence effectiveness of its patented DehydraTECHTM drug delivery technology across multiple classes of bioactive substances or drugs. In the weeks to come, Lexaria expects to announce many new studies designed to provide initial evidence expected to support further study and commercial exploitation. All studies referenced within this press release are fully funded from existing Company resources. finance.yahoo.com
NASDAQ:LEXX
by AlenCiken
TYME Granted U.S. Patent Claims Treat COVID-19 InfectionsTYME Granted U.S. Patent Claims Covering Use of TYME-19 to Treat COVID-19 Infections TYME announced that it has received notification that the United States Patent and Trademark Office has granted additional patent claims related to the Company’s metabolomic technology platform. The patent, U.S. Patent No. 10,905,698, is directed to methods for treating COVID-19. Unlike immune therapies that depend upon the structure of the external virus coat of COVID-19 where the therapy directs its attack, we believe TYME-19 is agnostic to this structure and any mutations to the viral coat. TYME intends to initiate the appropriate clinical trials to substantiate the safety and efficacy of TYME-19. TYME-19 is an investigational compound that is not approved in the U.S. for any disease indication. finance.yahoo.com
T
by AlenCiken
1
Potential Development of an Oral COVID-19l VaccineAeterna Zentaris Announces Evaluation and Potential Development of an Oral Prophylactic Bacterial Vaccine Against COVID-19 Through Exclusive Option Agreement with Julius-Maximilians-University Wuerzburg - Company secures next step to continue to build-out pipeline of assets. - University researchers developed a proprietary and orally active bacterial vaccine platform technology currently undergoing pre-clinical studies for the prevention of coronavirus diseases, including COVID-19. - Aeterna Zentaris to evaluate the University’s coronavirus vaccine platform technology including COVID-19 under an exclusive option agreement. to evaluate a preclinical potential COVID-19 vaccine developed at the Julius-Maximilians-University Wuerzburg (the “University”), one of Germany’s leading research and teaching universities. The vaccine technology developed at the University uses a typhoid fever vaccine as a carrier strain and has the potential to be an orally active COVID-19 (SARS-CoV-2) live-attenuated bacterial vaccine. Under the option agreement entered into with the University, Aeterna has the right to negotiate an exclusive worldwide license to develop this technology for the prevention of coronavirus diseases, including COVID-19. A scientific advice meeting with the German authorities at Paul-Ehrlich Institute has been scheduled by the University to discuss a roadmap towards initiating a first-in-human clinical trial. finance.yahoo.com Aeterna expects to make a decision whether to exercise its option to negotiate a license for that technology by mid 2021.
A
by AlenCiken
Corona(Covid 19 vaccine) stock that can explode in 2021A little-known biotech is trying its hand at developing a coronavirus vaccine. Can it succeed? over the past year, Vaxart stock has soared over 1,250% because of its spot in the lucrative coronavirus vaccine race. Its stock performance even outpaced those of biotechs that have already brought their coronavirus vaccines to market, such as Moderna and BioNTech. In fact, over 30% of Vaxart stock has been sold short. Vaxart claims to have created an experimental coronavirus vaccine in the form of an oral tablet. One could potentially self-administer the vaccine pill, which is stable at room temperature. This would allow patients to order the vaccine online and have it delivered for at-home use. At the moment, Vaxart's experimental coronavirus vaccine is only in phase 1 clinical trials, with a new data readout expected by next week. Unfortunately, it's impossible to conclude how the experimental vaccine will work on humans from animal models. Hence, the candidate's phase 1 data release will likely be a make-or-break moment for Vaxart. Vaxart is under investigation by both the U.S. Securities and Exchange Commission (SEC) and the Department of Justice (DOJ) for insider trading and inaccurate statements regarding its role in Operation Warp Speed (OWS). Even though Vaxart has more than $133 million in cash and equivalents with no debt whatsoever, that's not nearly enough to move forward. Right now, it could cost billions of dollars to run a potential coronavirus vaccine through clinical trials involving tens of thousands of participants. The company will likely sell more stock to pay for its research and development (R&D) expenses or apply for grant funding -- just to stay afloat. Vaxart is far riskier than the other coronavirus vaccine drugmakers out there. Its corporate conduct is under federal investigation, and its vaccine candidate is in far too early a stage to draw any definitive conclusions about. With a market cap just south of $1 billion, it will undoubtedly become a very undervalued stock if it can bring a coronavirus vaccine to market. Moderna, which has done so, projects $11.7 billion in revenue from its mRNA-1273 vaccine alone. However, the probability of Vaxart achieving anything remotely similar is up for debate. Short-sellers and passionate bulls will be arguing over the stock for the next year. If you believe in Vaxart's science and have the stomach for a roller-coaster ride, then go for it.
NASDAQ:VXRT
by AlenCiken
COVID-19 Vaccine Demonstrates 89.3% Efficacy in UK Phase 3 TrialNovavax COVID-19 Vaccine Demonstrates 89.3% Efficacy in UK Phase 3 Trial First to Demonstrate Clinical Efficacy Against COVID-19 and Both UK and South Africa Variants Strong efficacy in Phase 3 UK trial with over 50% of cases attributable to the now-predominant UK variant and the remainder attributable to COVID-19 virus Clinical efficacy demonstrated in Phase 2b South Africa trial with over 90% of sequenced cases attributable to prevalent South Africa escape variant NVX-CoV2373, its protein-based COVID-19 vaccine candidate, met the primary endpoint, with a vaccine efficacy of 89.3%, in its Phase 3 clinical trial conducted in the United Kingdom (UK). Novavax also announced successful results of its Phase 2b study conducted in South Africa. Significant progress on PREVENT-19 Clinical Trial in US and Mexico finance.yahoo.com
NASDAQ:NVAX
by AlenCiken
COVID-19 Wave 2 trajectory still ongoing... SD, MY, ID and CNFirst up... obvious from November 2020 that Singapore was already heading towards a spike/Wave2. After so long, appears sthat the inevitable is happening, and projecting forwards, by end Feb or early March, the MACD histogram would be positive. Note that this has had happened to China, obvious int he MACD histograms since Octoboer 2020, through to December 2020 and has prompted localized lockdowns in the NorthEast of China. Malaysia and Indonesia unfortunately are not seeing any reprieve... not surprising, given the measures taken, too little too late, if at all. This eventually will pose problems for Singapore. No change in the trejectory as outlined months ago...
C
by Auguraltrader
Hyperinflation aheadOil the biggest traded commodity globally by far and therefor best indicator to detect commodity price inflation imho. From Investopedia artikel Why Didn't Quantitative Easing Lead to Hyperinflation? the following snippet: "During the Great Recession banks still had bad loans and toxic assets on their balance sheets as a result of the housing bubble burst and its aftershocks. While the central bank did increase the money supply sharply, banks used these funds to shore up their balance sheets and buffer toxic assets, rather than creating new loans." Expecting the banks to have continued with this responsible business model, hyperinflation will fall upon the world economy straight out of the blue imho. Very well possible the reason why the UJ Seasonality opening bell has us waiting since March '18 for its continuation. A confluence of circumstances leading up to the great recession of 2008 included economic disruptions such as SARS and a CDO housing bubble, a repeat of quite a similar series of events likely to unfold with COVID marking the start of it all..
TVC:USOILLong
by Deep-Peat-Shark
2
EDSA to Study Investigational Drug as Potential Rescue TheraphyEdesa Biotech to Study Its Investigational Drug as Potential Rescue Therapy EDSA has received regulatory approval from the U.S. Food and Drug Administration (FDA) and Health Canada to add a sub-study to its ongoing Phase 2/Phase 3 clinical study of its investigational drug, EB05, for the treatment of Acute Respiratory Distress Syndrome (ARDS) - the leading cause of death in COVID-19 patients. The sub-study will evaluate the drug as a potential rescue therapy for critically severe COVID-19 cases. This sub-study will allow us to potentially expand the use of EB05 to critically ill patients suffering from profound, medically refractory COVID-19 respiratory failure," Dr. Nijhawan said. finance.yahoo.com
NASDAQ:EDSA
by AlenCiken
S&P: Why your shorts aren't winningHave you been shorting this bull market wondering why you're not winning? I've been getting direct messages asking me when is it a good time to short or why when there is a reversal candle there is no follow through to the downside. Zooming out to the 2 day chart I think you can see why. We are in a massive uptrend channel since early last year right after the big COVID drop. THE TREND IS YOUR FRIEND As of today, I would not be trying to short or even go long. I think the market is too risky and is coming up to heavy resistance. We need a big pullback before I think the S&P becomes attractive. Where is that pullback? I may end up waiting to see it pullback closer to the bottom of the channel (with retest) to go long. I'll also take a breakout of the top of the channel (with retest). Why not short when it reaches to the top of the channel? We are in a strong uptrend and going short is not recommended. Some may take the short at the top of the channel and be rewarded. It's just not my type of trade. I like trades with higher probability. Hopefully this view makes it much more clear why if you've been shorting the market since March 2020, you have been on the wrong side of the trade. I will be a seller if the bottom of the channel breaks to the downside (with retest). Then I think shorting will become attractive. Good luck trading. "When it feels really right it's probably wrong and when it feels really wrong it's probably right."
OANDA:SPX500USD
by XYZ-Trader-
5